Click to Share
 

Rna Press Releases

+ Alert
+ Feed
Exclusive News
Topics Locations Industries Dates

By Bioo Scientific
The United States Patent and Trademark Office (USPTO) has issued U.S. patent US9255291 Oligonucleotide ligation, barcoding and methods and compositions for improving data quality and throughput using massively parallel sequencing to Bioo Scientific.
12531505
By SMi Group
Silenseed present exclusive clinical evidence on the effectiveness of siRNA against mutated KRAS in pancreatic cancer at RNA Therapeutics 2016
12521821
By SMi Group
RNA Therapeutics 2016, 15th & 16th February, Holiday Inn Kensington Forum, London UK
12515658
By SMi Group
Emerging oligonucleotide therapeutics presented in two exclusive keynote addresses at SMi's 7th annual RNA Conference next February in London.
12421234
By SMi Group
SMi Group are delighted to announce that John Johnston, MHRA Clinical Assessor from the Biologicals & Biotechnology Unit, will be joining the expert panel at it’s 6th annual RNA Therapeutics conference, taking place on 16th & 17th February in...
By Golden Helix, Inc.
Today Golden Helix, Inc. announced their first ever t-shirt design contest.
12294336
By GATC Biotech
GATC Biotech provides information for research on cell function and on how changes in transcriptional activity may reflect or contribute to diseases.
By Bio-Synthesis, Inc.
The next generation of nucleic acids, provided by Bio-Synthesis, is an ideal solution for the detection of small or highly similar DNA or RNA targets.
12191485
By Donald Danforth Plant Science Center
ST. LOUIS, MO, August 12, 2013 – The Donald Danforth Plant Science Center’s "Conversations" series, sponsored by Boeing, will continue on Thursday, August 29, 2013 with a reception at 5:15 p.m. and the program at 6:00 p.m.
12116189
By Mary Ann Liebert, Inc., publishers
New classes of drugs that can silence specific genes, such as small interfering RNAs (siRNAs), offer great therapeutic potential. But the specific delivery of siRNAs to target cells to exert their effects remains a significant challenge.
12084947
By Mary Ann Liebert, Inc., publishers
By targeting the specific mutation that causes the hereditary neuromuscular disease myotonic dystrophy, it is possible to neutralize the mutant RNA toxicity and minimize or even eliminate the disabling symptoms of the disease.
12080170
By Mary Ann Liebert, Inc., publishers
As scientists continue to unravel the complexity of the human genome and to uncover vital elements that play a role in both normal physiology and disease, one particular class of elements called noncoding RNAs is gaining a lot of attention.

All Press Releases

By Bioo Scientific
The United States Patent and Trademark Office (USPTO) has issued U.S. patent US9255291 Oligonucleotide ligation, barcoding and methods and compositions for improving data quality and throughput using massively parallel sequencing to Bioo Scientific.
12531505
By SMi Group
Silenseed present exclusive clinical evidence on the effectiveness of siRNA against mutated KRAS in pancreatic cancer at RNA Therapeutics 2016
12521821
By SMi Group
RNA Therapeutics 2016, 15th & 16th February, Holiday Inn Kensington Forum, London UK
12515658
By SMi Group
Emerging oligonucleotide therapeutics presented in two exclusive keynote addresses at SMi's 7th annual RNA Conference next February in London.
By SMi Group
SMi group are delighted to announce Advanced Cell Diagnostics as event sponsors for the 7th annual RNA Therapeutics show taking place on 15th and 16th February in London next year.
By Visiongain
The world RNAi therapies market will reach $391m in 2018 predicts new visiongain report A new report by visiongain predicts that the world RNAi therapies market will reach $391m in 2018.
12421234
By SMi Group
SMi Group are delighted to announce that John Johnston, MHRA Clinical Assessor from the Biologicals & Biotechnology Unit, will be joining the expert panel at it’s 6th annual RNA Therapeutics conference, taking place on 16th & 17th February in...
By SMi Group Ltd
SMi’s 6th annual RNA Therapeutics conference takes place on the 16th – 17th February 2015 in London, UK.
By Golden Helix, Inc.
Today, Golden Helix, Inc. announced a new initiative, Golden Helix Gives Back, which provides free analytic software to academic researchers without adequate funding.
By Golden Helix, Inc.
Today, Golden Helix, Inc. announced a collaboration with Dr. Jeffrey Moore, newly named Howard Hughes Medical Institute Professor of the University of Illinois at Urbana-Champaign.
By Golden Helix, Inc.
Today Golden Helix, Inc. announced their first ever t-shirt design contest.
12294336
By GATC Biotech
GATC Biotech provides information for research on cell function and on how changes in transcriptional activity may reflect or contribute to diseases.
By Bio-Synthesis, Inc.
The next generation of nucleic acids, provided by Bio-Synthesis, is an ideal solution for the detection of small or highly similar DNA or RNA targets.
12191485
By Donald Danforth Plant Science Center
ST. LOUIS, MO, August 12, 2013 – The Donald Danforth Plant Science Center’s "Conversations" series, sponsored by Boeing, will continue on Thursday, August 29, 2013 with a reception at 5:15 p.m. and the program at 6:00 p.m.
12116189
By Mary Ann Liebert, Inc., publishers
New classes of drugs that can silence specific genes, such as small interfering RNAs (siRNAs), offer great therapeutic potential. But the specific delivery of siRNAs to target cells to exert their effects remains a significant challenge.
12084947
By Mary Ann Liebert, Inc., publishers
By targeting the specific mutation that causes the hereditary neuromuscular disease myotonic dystrophy, it is possible to neutralize the mutant RNA toxicity and minimize or even eliminate the disabling symptoms of the disease.
12080170
By Mary Ann Liebert, Inc., publishers
As scientists continue to unravel the complexity of the human genome and to uncover vital elements that play a role in both normal physiology and disease, one particular class of elements called noncoding RNAs is gaining a lot of attention.
By Mary Ann Liebert, Inc., publishers
Small interfering RNAs (siRNAs) are a potent new drug class that can silence a disease-causing gene, but delivering them to a target cell can be challenging.
By Mary Ann Liebert, Inc., publishers
The use of RNA in nanotechnology applications is highly promising for many applications, including the development of new therapeutic compounds.
By AnaSpec EGT Group
The detection of nucleic acids is important for many life science research tasks, such as sequencing, cDNA synthesis and cloning, RNA transcription and transfection.
By biosyn.com
Bio-Synthesis is able to synthesize ultra long oligonucleotides (RNA and DNA).
By Mary Ann Liebert, Inc., publishers
Small RNA-based nucleic acid drugs represent a promising new class of therapeutic agents for silencing abnormal or overactive disease-causing genes, and researchers have discovered new mechanisms by which RNA drugs can control gene activity.
By Shridhar University
Even though the proponents of a natural origin of life expressed much optimism for providing their theories, presently there is a detailed compilation of information seriously questioning this doctrine.
11659522
By Particular GmbH
While the gold price keeps setting new records, nanoparticles from pure gold are also gaining importance in biotechnology. Particular GmbH from Germany now uses a laser method to produce them with high purity and conjugate them with high efficiency.
By Freedom Press
New Book “Extraordinary Healing” recounts life and research of French molecular biologist Dr. Mirko Beljanski
By Insight Pharma Reports
RNAi Therapeutics: Second-Generation Candidates Build Momentum
By Bharatbook
Bharatbook added a new report on "Global miRNA Market Outlook" which provides a comprehensive overview of the miRNA market and its prospects. By RNCOS.
By Melanie Bernds
Dr. William H. Danforth, chairman of the Board of Trustees of the Donald Danforth Plant Science Center, today announced that Dr. James C. Carrington, will become the next President of the Danforth Plant Science Center.
By Insight Pharma Reports
Cambridge Healthtech Institute (CHI) releases its latest Insight Pharma Report, Next-Generation Sequencing Technologies: Applications and Markets, available at InsightPharmaReports.com
By Bill Schappert
Antigene therapy is a promising new treatment strategy that uses a DNA-based drug to pinpoint light energy to a target gene shutting down its activity. A review article published online ahead of print in Oligonucleotides.

Page:
Page updated every 10 minutes


Like PRLog?
9K2K1K
Click to Share